CBD shown to curb alcohol cravings? phase 2 trial launches.
NCT ID NCT07279558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether cannabidiol (CBD) can help people who drink alcohol regularly cut down on their drinking. Researchers are giving 150 adults either full-spectrum CBD, broad-spectrum CBD, or a placebo daily for 12 weeks. They will measure how much participants drink in a lab setting and through self-reports, as well as blood markers of alcohol use. The goal is to see if CBD can be a safe, effective tool for managing alcohol use disorder.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cannabidiol (CBD) – either full-spectrum (with trace THC) or broad-spectrum (no THC)
- What this could lead to
- If it works, this could point toward a new, non-addictive option to help people drink less and avoid alcohol-related harm.
- What could go wrong
- This is a mid-stage trial with only 150 participants, so results may not apply to everyone. CBD may not reduce drinking more than a placebo, and some people may experience side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 21-65 2. Have used CBD and cannabis at least once in the last year 3. Regularly drink alcohol 4. Able to provide informed consent and attend in-person study visits Exclusion Criteria: 1. Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol 2. Current use of antiepileptic medication or any psychotropic medication besides antidepressants 3. Pregnant, nursing, or planning a pregnancy 4. Medical conditions that contraindicates the use of CBD or alcohol 5. Current medical conditions that may require intensive care during the study period Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Colorado School of Medicine- Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Investigating the Mu:Kappa opioid receptor imbalance in alcohol use disorder
- Identification of cellular and molecular mechanisms involved in the pathophysiology of alcohol use disorder by examination of cerebrospinal fluid
- Intravenous acetate as an adjunctive treatment for alcohol withdrawal in hospitalized patients
- Can a gentle brain current quiet alcohol cravings?
- Brain imaging may expose a shared marker in PTSD and alcohol addiction
- Could a seizure drug curb alcohol withdrawal in trauma wards?